Medicaid Drug Rebates

CMS Keynote Presentation

John Coster Director, Division of Pharmacy CMS

Now that the AMP Final Rule is here, join industry experts, leading stakeholders, outside counsel, and colleagues to better understand the rule, its impact, and how your pricing, contracting, and reporting processes need to be updated to ensure compliance. World Congress’s Medicaid Drug Rebates Summit is a can’t-miss opportunity to network, share best practices, and discuss challenges with implementing the changes in the Final Rule.

Join Janssen Pharmaceuticals, Pfizer, Astellas, Horizon Pharma, Shire, BIO, Acorda Therapeutics, Eli Lilly and Company, NCPDP, Arnold & Porter, Jazz Pharmaceuticals, Sidley Austin, and many more to discuss key issues including:

• Break down the Final Rule and Understand Major Areas of Impact
• Develop best practices for working cross-functionally with IT and legal departments to update processes, testing reporting procedures, and implement any required changes
• Understand how the rule impacts pricing calculations including BP, 340B ceiling prices, and AMP
• Implement the Alternative Rebate Formula and understand the inclusions and exclusions for line extensions and differentiate between increasing the drug strength versus a reformulation
• Determine the definition of RCPs and assess how that affects the alternative AMP calculation for 5i drugs
• Discuss best practices for government pricing compliance and examine the latest enforcement trends to develop strategies and build tools to mitigate your risk
• Gain insights on the “must offer” provision in the 340B Omnibus Guidance and the impact on new drug pricing and understand how the proposed 340B Omnibus Guidance impacts pricing
• Overcome challenges with coverage restrictions and price controls for specialty products